Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $14.62, up 0.41% from its previous closing price of $14.56. In other words, the price has increased by $0.41 from its previous closing price. On the day, 1.53 million shares were traded. ARQT stock price reached its highest trading level at $14.98 during the session, while it also had its lowest trading level at $14.36.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.46. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 0.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’25 when Welgus Howard G. bought 10,000 shares for $14.67 per share.
Burnett Patrick sold 1,691 shares of ARQT for $23,674 on Dec 31 ’24. The insider now owns 126,978 shares after completing the transaction at $14.00 per share. On Dec 31 ’24, another insider, Burnett Patrick, who serves as the Officer of the company, bought 1,691 shares for $13.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1711197824 and an Enterprise Value of 1588808960. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.39 while its Price-to-Book (P/B) ratio in mrq is 10.92. Its current Enterprise Value per Revenue stands at 11.454 whereas that against EBITDA is -8.856.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $15.79, while it has fallen to a 52-week low of $3.11. The 50-Day Moving Average of the stock is 26.49%, while the 200-Day Moving Average is calculated to be 46.18%.
Shares Statistics:
It appears that ARQT traded 2.05M shares on average per day over the past three months and 2172100 shares per day over the past ten days. A total of 117.00M shares are outstanding, with a floating share count of 102.97M. Insiders hold about 12.03% of the company’s shares, while institutions hold 103.05% stake in the company. Shares short for ARQT as of 1734048000 were 23111209 with a Short Ratio of 11.29, compared to 1731628800 on 25015963. Therefore, it implies a Short% of Shares Outstanding of 23111209 and a Short% of Float of 24.430001.
